期刊文献+

肾母细胞瘤组织中组织蛋白酶D、尿激酶型纤溶酶原激活剂及其受体的表达

Expression of Cath D, uPA, and uPAR in nephroblastoma
下载PDF
导出
摘要 目的:探讨肾母细胞瘤组织中Cath D、uPA、uPAR的表达。方法:用免疫组化SABC法检测30例肾母细胞瘤及15例非肿瘤肾组织中Cath D、uPA、uPAR的表达。结果:肾母细胞瘤组织中Cath D、uPA、uPAR的阳性表达率分别为50%,53.3%和56.7%。而在非肿瘤肾组织中不表达,差异有统计学意义(P<0.05),3者的阳性表达率与组织学类型密切相关,FH型均低于UH型(P<0.05)..结论:Cath D、uPA、uPAR在肿瘤的浸润和转移中起重要作用,可作为预后的指标。 Aim : To detect the expressions of Cath D, urokinase-type plasminogen activator ( uPA) and its receptor (uPAR) in nephroblastoma and reveal the correlation with histological type. Methods: The expressions of Cath D, uPA and uPAR as well as its correlationship with tumor histological type in 30 specimens of nephroblastoma and 15 non-tumor kidney tissues were retrospectively studied by using SABC immunohistochemistry. Results: The positive rates of expression of Cath D , upA , uPAR in nephroblastoma group were 50% , 53. 3% , 56. 7% respectively, but there were no positive staining in non-tumor kidney tissues. There were significant difference(P <0.05). The expressions of Cath D, uPA, uPAR were closely related to histological type. The expressions in FH were weaker than in UH ( P <0. 05). Conclusion; The findings suggest that Cath D, uPA and uPAR play an important role in invasion and metastasis of nephroblastoma. Cath D, uPA and uPAR might be independent predictors of prognosis.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2004年第2期217-219,共3页 Journal of Zhengzhou University(Medical Sciences)
基金 河南省科技攻关基金资助项目 324410085
关键词 织蛋白酶D 尿激酶型纤溶酶原激活剂 尿激酶型纤溶酶原激活剂受体 肾母细胞瘤 免疫组化 组织学类型 预后 Cath D uPA uPAR nephroblastoma immunohistochemistry histological type prognosis
  • 相关文献

参考文献11

  • 1王勇,毛伯镛,张尚福,程宏伟.尿激酶型纤溶酶原激活剂在髓母细胞瘤中的表达及意义[J].华西医科大学学报,2001,32(3):376-378. 被引量:1
  • 2李鹏,高亚,李恭才,张宪生,徐泉,郭正团.尿激酶型纤溶酶原激活因子及其受体在神经母细胞瘤中的表达及其意义[J].中华实验外科杂志,2002,19(2):137-138. 被引量:5
  • 3Chodynicki S, Chyczewski L, Olazewska E. Immunohistochemical investigations of cathepsin D activity in the structures of cholesteatoma. Med Sci Monit ,2002,8 ( 5 ): BR184. 被引量:1
  • 4Kin Y, Chintala SK, Go Y, et al. A novel role for the urokinase type plasminogen activator receptor in apoptosis of malignant gliomas. In J Oncol,2000,17 ( 1 ) :61. 被引量:1
  • 5Beckwith JB. National Wilms Tumor Study: an update for pathologists. Pediatr Dev Pathol, 1998,1 ( 1 ) :79. 被引量:1
  • 6Macchione E, Epifano O, Stefanini M,et al. Urokinase redistribution from the secreted to the cell-bound fraction in granulose cells of rat preovulatory follicles. Biol Reprod,2000,62(4) :895. 被引量:1
  • 7Montuori N, Mattiello A, Mancini A, et al. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma. Int J Cancer,2003,105 (3) :353. 被引量:1
  • 8Celentano DC, Frishman WH. Matrix metalloproteinases and coronary artery disease:a novel therapeutic targer. J Clin Pharmacol, 1997,37 ( 11 ): 991. 被引量:1
  • 9Peverali FA, Mandriota SJ, Ciana P, et al. Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression invascular endothelial cells. J Cell Physiol, 1994,161 ( 1 ) :1. 被引量:1
  • 10Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am,2001,10(2) :393. 被引量:1

二级参考文献13

  • 1[1]Yamamoto M, Sawaya R, Mohanam S, et al. Expression and local izat ion of urokinase-type plasminogen activator receptor in human astrocytomas in vivo. Cancer Res, 1994 ;54(14) :3656 被引量:1
  • 2[2]MacDonald TJ,DeClerck YA,Laug WE. Urokinase induces recepor media ted brain tumor cell migration and invasion. J Neurooncol, 1998; 40(3):215[ ZK) 被引量:1
  • 3[3]Yamamoto M, Sawaya R, Mohanam S, et al. Expression and local ization of urokinase -type plasminogen activator receptor in human gliomas. Ca ncer Res, 1994; 54(18) :5016 被引量:1
  • 4[4]David KM,Casey ATH,Hayward RD,et al. Medulloblastoma:Is the 5 - year survival rate improving? J Neurosurg,1997; 86(1):13 被引量:1
  • 5[5]Berkman RA, Efird JT, Hedley-Whyte ET, et al. Expression of th e vascular permeability factor/vascular endothelial growth factor gene in cent ral nervous system neoplasms.J Clin Invest, 1993; 91(1):153 被引量:1
  • 6[6]Kitange G,Shibata S,Tokunaga Y,et al.Ets-1 transcription fac tor-mediated urokinase-type plasminogen activator expression and invasion in g lioma cells stimulated by serum and basic fibroblast growth factors.Lab Invest, 1999; 79(4):407 被引量:1
  • 7[7]Nakada M,Yamashita J,Okada Y,et al. Ets-1positively regulate s expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors.J Neuropathol Exp Neurol, 1999; 58(4):329 被引量:1
  • 8[8]Hildenbrand R,Dilger l.Horlin A,et al. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Patho l Res Pract,1995; 191(5):403 被引量:1
  • 9[9]Hsu DW,Efird JT,Hedley-Whyte ET.Prognostic role of urokinase-ty pe plasminogen activator in human gliomas. Am J Pathol, 1995; 147(1):114 被引量:1
  • 10Brodeur GM,Pritchard J,Berthold,et al.Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment[].Journal of Clinical Oncology.1993 被引量:1

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部